Share on StockTwits

RXi Pharmaceuticals Corp (NASDAQ:RXII) announced its earnings results on Wednesday. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.31) by $0.01, AnalystRatings.Net reports.

Several analysts have recently commented on the stock. Analysts at Wainwright initiated coverage on shares of RXi Pharmaceuticals Corp in a research note on Monday, May 5th. They set a “buy” rating and a $9.00 price target on the stock. Analysts at HC Wainwright initiated coverage on shares of RXi Pharmaceuticals Corp in a research note on Monday, May 5th. They set a “buy” rating and a $9.00 price target on the stock.

RXi Pharmaceuticals Corp (NASDAQ:RXII) opened at 3.17 on Wednesday. RXi Pharmaceuticals Corp has a one year low of $2.55 and a one year high of $6.84. The stock has a 50-day moving average of $3.68 and a 200-day moving average of $3.97. The company’s market cap is $42.4 million.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) is a development-stage company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.